

DAFTAR PUSTAKA

- Abrahamson, M., Mason, R.W., Hansson, H. Human cystatin C role of the N-terminal segment in the inhibition of human cysteine proteinases and in its inactivation by leucocyte elastase. 1991. *Biochem. J.* 273. 621–626.
- Abrahamson, M., Alvarez-Fernandez, M., Nathanson C.J. Cystatins. 2003. *Biochem. Soc. Symp.* 70 (2003) 179–199.
- Al-Beladi, F. I. 2015. Cystatin C is an Early Marker of Contrast-Induced Nephropathy in Patients with Sepsis in the Intensive Care Unit. In *Saudi J Kidney Dis Transpl* (Vol. 26, Issue 4). <http://journals.lww.com/sjkd>
- Al-Tu'ma, F.J., Dheyauldeen, M.H., Almukhtar, M.A., Al Jawad, S.Y., Al-Saegh, R.M. The Role of Serum Cystatin C in the Early Detection of Contrast-Induced Nephropathy after Coronary Intervention. 2017. *J Kidney.* 3: 154.
- Amsterdam, E.A., Wenger, N.K., Brindis, R.G., Casey Jr., D.E, Ganiats T.G., Holmes Jr., D.R., *et al.*, [ACC/AHA Task Force Members](#). 2014 AHA/ACC Guideline for the Management of Patients with Non-ST- Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014. *J Am Coll Cardiol.* 64(24):e139-e228.
- Andreucci, M., Faga, T., Pisani, A., Sabbatini, M., Russo, D., Michael A. 2014. The Choice of the Iodinated Radiographic Contrast Media to Prevent Contrast-Induced Nephropathy. *Advances in Nephrology.* 11 pages.
- Ashalatha, V. L., Bitla, A. R., Kumar, V. S., Rajasekhar, D., Suchitra, M. M., Lakshmi, A. Y., Rao, P. V. L. N. S. 2017. Biomarker response to contrast administration in diabetic and nondiabetic patients following coronary angiography. *Indian Journal of Nephrology*, 27(1), 20–27. <https://doi.org/10.4103/0971-4065.179335>
- Aspelin, P., Aubry, P., Fransson, S.-G., Strasser, R., Willenbrock, R., Berg, K. J. 2003. Nephrotoxic Effects in High-Risk Patients Undergoing Angiography. In *n engl j med* (Vol. 348). www.nejm.org
- Azzalini, L., Spagnoli, V., Ly, H. Q. 2016. Contrast-Induced Nephropathy: From Pathophysiology to Preventive Strategies. In *Canadian Journal of Cardiology* (Vol. 32, Issue 2, pp. 247–255). Pulsus Group Inc. <https://doi.org/10.1016/j.cjca.2015.05.013>

- Barrett, A.J. Cystatin, the egg white inhibitor of cysteine proteinases. 1981. *Meth. Enzymol.* 80. 771–778.
- Benko, A., Fraser-Hill, M., Magner, P., Capusten, B., Barrett, B., Myers, A., Owen, R. J., Canadian Association of Radiologists. 2007. Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy. *Canadian Association of Radiologists Journal = Journal l'Association Canadienne Des Radiologistes*, 58(2), 79–87. <http://www.ncbi.nlm.nih.gov/pubmed/17521052>
- Bobek, L. A., & Levine, M. J. 1992. Cystatins--inhibitors of cysteine proteinases. *Critical Reviews in Oral Biology and Medicine : An Official Publication of the American Association of Oral Biologists*, 3(4), 307–332. <https://doi.org/10.1177/10454411920030040101>
- Briguori, C., Visconti, G., Rivera, N. v., Focaccio, A., Golia, B., Giannone, R., *et al.* 2010. Cystatin C and contrast-induced acute kidney injury. *Circulation*, 121(19), 2117–2122. <https://doi.org/10.1161/CIRCULATIONAHA.109.919639>
- Cely, C. M., Schein, R. M. H., Quartin, A. A. 2012. Risk of contrast induced nephropathy in the critically ill: A prospective, case matched study. *Critical Care*, 16(2). <https://doi.org/10.1186/cc11317>
- Chong, E., Poh, K. K., Shen, L., Chai, P., & Tan, H. C. 2009. Diabetic patients with normal baseline renal function are at increased risk of developing contrast-induced nephropathy post-percutaneous coronary intervention. *Singapore Medical Journal*, 50(3), 250–254. <http://www.ncbi.nlm.nih.gov/pubmed/19352566>
- Christopher, O., Xu, X. F., Lin, Y. F., Zhang, S. Z., Huang, Y. Q., Zhong, X. bin, *et al.* 2021. Association between serum cystatin C level and hemodynamically significant aortic stenosis: A prospective cohort study. *Journal of Geriatric Cardiology*, 18(12), 986–995. <https://doi.org/10.11909/j.issn.1671-5411.2021.12.003>
- Ciach, E., Bobilewicz, D. The use of cystatin C concentration in the assessment of glomerular filtration rate in children and elderly population. 2012. *J. Lab. Diagn.* 48. 423–431.
- Clausen, J. 1961. Proteins in Normal Cerebrospinal Fluid Not Found in Serum. *Experimental Biology and Medicine*, 107(1), 170–172. <https://doi.org/10.3181/00379727-107-26569>

- Delanaye, P., White, C. A., Ebert, N., Rule, A. D. 2019. Assessing Kidney Function. In *Chronic Renal Disease* (pp. 37–54). Elsevier. <https://doi.org/10.1016/B978-0-12-815876-0.00004-8>
- Elsayed, M. S., el Badawy, A., Ahmed, A., Omar, R., Mohamed, A. 2019. Serum cystatin C as an indicator for early detection of diabetic nephropathy in type 2 diabetes mellitus. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, 13(1), 374–381. <https://doi.org/10.1016/j.dsx.2018.08.017>
- Fan, L., Inker, L.A., Rossert, J., Froissart, M., Rossing P., Mauer M., Andrew, S.L. Glomerular filtration rate estimation using cystatin C alone or combined with creatinine as a confirmatory test. 2014. *Nephrology Dialysis Transplantation*. Volume 29, Issue 6, Pages 1195–1203.
- Filler, G., Bökenkamp, A., Hofmann, W., le Bricon, T., Martínez-Brú, C., Grubb, A. 2005. Cystatin C as a marker of GFR - History, indications, and future research. *Clinical Biochemistry*, 38(1), 1–8. <https://doi.org/10.1016/j.clinbiochem.2004.09.025>
- Fiorentino, T. V., Prioletta, A., Zuo, P., & Folli, F. (2013). Send Orders for Reprints to reprints@benthamscience.net Hyperglycemia-induced Oxidative Stress and its Role in Diabetes Mellitus Related Cardiovascular Diseases. In *Current Pharmaceutical Design* (Vol. 19).
- Froissart, M., Rossert, J., Jacquot, C., Paillard, M., Houillier, P. 2005. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. *Journal of the American Society of Nephrology*, 16(3), 763–773. <https://doi.org/10.1681/ASN.2004070549>
- Levy, E., Lopez-Otin, C., Ghiso, J., Geltner, D., Frangione, B. Stroke in Icelandic patients with hereditary amyloid angiopathy is related to a mutation in the cystatin C gene, an inhibitor of cysteine proteases. 1989. *J. Exp. Med.* 1. 1771–1778.
- Goldfarb, S., Spinler, S., Berns, J.S., Rudnick, M.R. Low-osmolality contrast media and the risk of contrast-associated nephrotoxicity. 1993. *Invest Radiol.* 28:Suppl 5: S7-10.
- Grubb, A., & Löfberg, H. 1982. Human gamma-trace, a basic microprotein: amino acid sequence and presence in the adenohypophysis. *Proceedings of the National Academy of Sciences of the United States of America*, 79(9), 3024–3027. <https://doi.org/10.1073/pnas.79.9.3024>
- Grubb, A. 1992. Diagnostic value of analysis of cystatin C and protein HC in biological fluids. *Clinical Nephrology*, 38 Suppl 1, S20-7.

- Guillon, B., Ecartot, F., Marcucci, C., Ducloux, D., Chatot, M., Badoz, M., *et al.* 2018. Incidence, Predictors, and Impact on Six-Month Mortality of Three Different Definitions of Contrast-Induced Acute Kidney Injury After Coronary Angiography. *American Journal of Cardiology*, 121(7), 818–824. <https://doi.org/10.1016/j.amjcard.2017.12.029>
- Heyman, S. N., Rosenberger, C., Rosen, S., Khamaisi, M. 2013. Why is diabetes mellitus a risk factor for contrast-induced nephropathy? In *BioMed Research International* (Vol. 2013). <https://doi.org/10.1155/2013/123589>
- Hinson, J. S., Ehmann, M. R., Fine, D. M., Fishman, E. K., Toerper, M. F., Rothman, R. E., Klein, E. Y. 2017. Risk of Acute Kidney Injury After Intravenous Contrast Media Administration. *Annals of Emergency Medicine*, 69(5), 577-586.e4. <https://doi.org/10.1016/j.annemergmed.2016.11.021>
- Inker, L. A., Schmid, C. H., Tighiouart, H., Eckfeldt, J. H., Feldman, H. I., Greene, T., Kusek, J. W., Manzi, J., van Lente, F., Zhang, Y. L., Coresh, J., Levey, A. S. 2012. Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C. *New England Journal of Medicine*, 367(1), 20–29. <https://doi.org/10.1056/nejmoa1114248>
- Inker, L. A., Levey, A. S. 2018. Measurement and Estimation of Kidney Function. In *Chronic Kidney Disease, Dialysis, and Transplantation: A Companion to Brenner and Rector's The Kidney* (pp. 23-41.e3). Elsevier. <https://doi.org/10.1016/B978-0-323-52978-5.00002-1>
- Ivan, F., Isorni, M. A., Halimi, J. M., Fauchier, L., saint Etienne, C., Babuty, D., Angoulvant, D., & Brunet-Bernard, A. 2014. Predictive factors of contrast-induced nephropathy in patients undergoing primary coronary angioplasty. *Archives of Cardiovascular Diseases*, 107(8–9), 424–432. <https://doi.org/10.1016/j.acvd.2014.05.008>
- Iyos, R. N., Utami, N., & Wijaya, S. M. (2017). Hubungan Sindrom Koroner Akut dengan Riwayat Diabetes Melitus di RSUD Dr. H. Abdoel Moeloek. In *JK Unila* | (Vol. 1).
- Jafferani, A., Shoukat, S., Gowani, S. A., Dhakam, S. H. 2010. Contrast-induced nephropathy in patients undergoing percutaneous coronary intervention. In *Cardiology Research and Practice* (Vol. 1, Issue 1). <https://doi.org/10.4061/2010/649164>
- Jiborn, T., Abrahamson, M., Wallin, H., Cystatin C is highly expressed in the human male reproductive system. 2004. *J. Androl.* 25. 564–572.

- Kim, T. H., Lee, H. A., Seo, Y. S., Lee, Y. R., Yim, S. Y., *et al.* 2019. Assessment and prediction of acute kidney injury in patients with decompensated cirrhosis with serum cystatin C and urine N-acetyl- β -D-glucosaminidase. *Journal of Gastroenterology and Hepatology (Australia)*, 34(1), 234–240. <https://doi.org/10.1111/jgh.14387>
- Kosasih, E. N. 2008. *Tafsiran Hasil Pemeriksaan Klinik*. 2nd ed. Karisma Publishing Group, Jakarta
- Levy, E., Lopez-Otin, C., Ghiso, J., Geltner, D., Frangione, B. 1989. Stroke in Icelandic patients with hereditary amyloid angiopathy is related to a mutation in the cystatin C gene, an inhibitor of cysteine proteases. *The Journal of Experimental Medicine*, 169(5), 1771–1778. <https://doi.org/10.1084/jem.169.5.1771>
- Lin, K., Zheng, W., Bei, W., Chen, S., Islam, S. M. S., Liu, Y., *et al.* 2017. A novel risk score model for prediction of contrast-induced nephropathy after emergent percutaneous coronary intervention. *International Journal of Cardiology*, 230, 402–412. <https://doi.org/10.1016/j.ijcard.2016.12.095>
- Liu, Y., Tan, N., Zhou, Y. L., He, P. C., Luo, J. F., Chen, J. Y. 2012. The contrast medium volume to estimated glomerular filtration rate ratio as a predictor of contrast-induced nephropathy after primary percutaneous coronary intervention. *International Urology and Nephrology*, 44(1), 221–229. <https://doi.org/10.1007/s11255-011-9910-4>
- Mamoulakis, C., Tsarouhas, K., Fragkiadoulaki, I., Heretis, I., Wilks, M. F., Spandidos, D. A., *et al.* 2017. Contrast-induced nephropathy: Basic concepts, pathophysiological implications and prevention strategies. In *Pharmacology and Therapeutics* (Vol. 180, pp. 99–112). Elsevier Inc. <https://doi.org/10.1016/j.pharmthera.2017.06.009>
- Marenzi, G., Marana, I., Lauri, G., Assanelli, E., Grazi, M., Campodonico, J., Trabatttoni, D., Fabbicchi, F., Montorsi, P., & Bartorelli, A. L. 2003. The Prevention of Radiocontrast-Agent-Induced Nephropathy by Hemofiltration. In *n engl j med* (Vol. 14). www.nejm.org
- McCullough, P. A., Adam, A., Becker, C. R., Davidson, C., Stacul, F., Tumlin, J., *et al.* 2006. Risk prediction of contrast-induced nephropathy. *The American journal of cardiology*. 98(6A), 27K–36K. <https://doi.org/10.1016/j.amjcard.2006.01.022>
- McCullough, P. A. 2008. Contrast-induced acute kidney injury. *J Am Coll Cardiol*. 51:1419–28.

- McCullough, P. A, Choi, J. P, Feghali, G. A., Schussler, J. M, Stoler, R. M., Vallabahn, R. C., Mehta, A. 2016. Contrast-Induced Acute Kidney Injury. *Journal of the American College of Cardiology*. 68:1465–73.
- Mehran, R., Nikolsky, E. 2006. Contrast-induced nephropathy: Definition, epidemiology, and patients at risk. *Kidney International*, 69(SUPPL. 100). <https://doi.org/10.1038/sj.ki.5000368>
- Mehran, R., Dangas, G. D., Weisbord, S. D. 2019. Contrast-Associated Acute Kidney Injury. *New England Journal of Medicine*, 380(22), 2146–2155. <https://doi.org/10.1056/nejmra1805256>
- Morcos, R., Kucharik, M., Bansal, P., al Taii, H., Manam, R., Casale, J., *et al.* 2019. Contrast-Induced Acute Kidney Injury: Review and Practical Update. In *Clinical Medicine Insights: Cardiology* (Vol. 13). SAGE Publications Ltd. <https://doi.org/10.1177/1179546819878680>
- Mostafa, A., Al-Hendy, A., Emara, A., Adly, E. 2016. Cystatin C as an early diagnostic marker for contrast nephropathy in diabetic patients undergoing coronary angiography. *Menoufia Medical Journal*, 29(1), 60. <https://doi.org/10.4103/1110-2098.178981>
- Mussap, M., & Plebani, M. 2004. Biochemistry and clinical role of human cystatin C. *Critical Reviews in Clinical Laboratory Sciences*, 41(5–6), 467–550. <https://doi.org/10.1080/10408360490504934>
- Nauta, F. L., Boertien, W. E., Bakker, S. J. L., van Goor, H., van Oeveren, W., de Jong, P. E., *et al.* 2011. Glomerular and tubular damage markers are elevated in patients with diabetes. *Diabetes Care*, 34(4), 975–981. <https://doi.org/10.2337/dc10-1545>
- Nikolsky, E., Mehran, R., Lasic, Z., Mintz, G.S., Lansky, A.J., Na, Y., *et al.* Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. 2005. *Kidney Int.* 67:706–13.
- Ningrum, N. R., Yuniadi, Y. 2009. Contrast Induced Nephropathy. *Jurnal Kardiologi Indonesia J Kardiol Indones*, 30(2), 71–80.
- Nozue, T., Michishita, I., Iwaki, T., Mizuguchi, I., & Miura, M. (2009). Contrast medium volume to estimated glomerular filtration rate ratio as a predictor of contrast-induced nephropathy developing after elective percutaneous coronary intervention. *Journal of Cardiology*, 54(2), 214–220. <https://doi.org/10.1016/j.jjcc.2009.05.008>
- Onopiuk, A., Tokarzewicz, A., Gorodkiewicz, E. Cystatin C: A Kidney Function Biomarker. 2015. *Elsevier Inc. Advances in Clinical Chemistry*. Volume 68.

- Padhy, M., Kaushik S., Girish, M.P., Mohapatra, S., Shah, S., Koner, B.C. Serum neutrophil gelatinase associated lipocalin (NGAL) and cystatin C as early predictors of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention. 2014. *Clinica Chimica Acta*. Volume 435, Pages 48-52.
- Parfrey, P.S., Griffiths, S.M., Barrett, B.J., Paul, M.D., Genge, M., Withers, J., *et al.* Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. 1989. *N Engl J Med*. 320:143–9.
- Park, H. S., Kim, C. J., Yi, J. E., Hwang, B. H., Kim, T. H., Koh, Y. S., *et al.* 2015. Contrast volume/raw eGFR ratio for predicting contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention for myocardial infarction. *CardioRenal Medicine*, 5(1), 61–68. <https://doi.org/10.1159/000369940>
- Patschan, D., Buschmann, I., Ritter, O. 2018. Contrast-Induced Nephropathy: Update on the Use of Crystalloids and Pharmacological Measures. In *International Journal of Nephrology* (Vol. 2018). Hindawi Limited. <https://doi.org/10.1155/2018/5727309>
- PERKENI. 2021. *Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia*. PERKENI, Jakarta
- Pflueger, A., Larson, T. S., Nath, K. A., King, B. F., Gross, J. M., & Knox, F. G. 2000. Role of adenosine in contrast media-induced acute renal failure in diabetes mellitus. In *Mayo Clinic Proceedings* (Vol. 75, Issue 12, pp. 1275–1283). Elsevier Ltd. <https://doi.org/10.4065/75.12.1275>
- Rawlings, N.D., Barrett, A.J. Evolution of proteins of the cystatin superfamily. 1990. *J. Mol. Evol.* 30. 60–71.
- Rear, R., Bell, R. M., Hausenloy, D. J. 2016. Contrast-induced nephropathy following angiography and cardiac interventions. *Heart*, 102(8), 638–648. <https://doi.org/10.1136/heartjnl-2014-306962>
- Rihal, C. S., Textor, S. C., Grill, D. E., Berger, P. B., Ting, H. H., Best, P. J., *et al.* 2002. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. *Circulation*, 105(19), 2259–2264. <https://doi.org/10.1161/01.CIR.0000016043.87291.33>
- Rizvi, M. S., Kashani, K. B. 2017. Biomarkers for Early Detection of Acute Kidney Injury. *The Journal of Applied Laboratory Medicine*, 2(3), 386–399. <https://doi.org/10.1373/jalm.2017.023325>

- Rudnick, M.R., Goldfarb, S., Wexler, L., Ludbrook, P.A., Murphy M.J., Halpern, E.F., *et al.* 1995. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial: the Iohexol Cooperative Study. *Kidney Int.* 47:254-61.
- Sahakyan, K., Lee, K. E., Shankar, A., & Klein, R. 2011. Serum cystatin C and the incidence of type 2 diabetes mellitus. *Diabetologia*, 54(6), 1335–1340. <https://doi.org/10.1007/s00125-011-2096-6>
- Sgura, F.A., Bertelli, L. Monopoli, D., Leuzzi, C., Guerri, E., Sparta', I., *et al.* 2010. Mehran contrast-induced nephropathy risk score predicts short and long-term clinical outcomes in patients with ST-elevation- myocardial infarction. 2010. *Circ Cardiovasc Interv.* 3:491-8.
- Shankar, A., Teppala, S. 2011. Relationship between serum cystatin C and hypertension among US adults without clinically recognized chronic kidney disease. *Journal of the American Society of Hypertension*, 5(5), 378–384. <https://doi.org/10.1016/j.jash.2011.03.003>
- Shukla, A. N., Juneja, M., Patel, H., Shah, K. H., Konat, A., Thakkar, B. M., *et al.* 2017. Diagnostic accuracy of serum cystatin C for early recognition of contrast induced nephropathy in Western Indians undergoing cardiac catheterization. *Indian Heart Journal*, 69(3), 311–315. <https://doi.org/10.1016/j.ihj.2016.12.010>
- Solomon, R., Dauerman, H. L. 2010. Contrast-induced acute kidney injury. *Circulation*, 122(23), 2451–2455. <https://doi.org/10.1161/CIRCULATIONAHA.110.953851>
- Stevens, L. A., Padala, S., Levey, A. S. 2010. Advances in glomerular filtration rate-estimating equations. In *Current Opinion in Nephrology and Hypertension* (Vol. 19, Issue 3, pp. 298–307). <https://doi.org/10.1097/MNH.0b013e32833893e2>
- Tsai, T.T., Patel, U.D., Chang, T.I., Kennedy, K.F., Masoudi, F.A., Matheny, M.E., *et al.* 2014. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. *JACC Cardiovasc Interv.* 7:1-9.
- Vaidya, V.S., Ferguson, M.A., Bonventre, J.V. 2008. Biomarkers of acute kidney injury. *Annu Rev Pharmacol Toxicol.* 48: 463-493.

- Vallabhajosyula, S., Jentzer, J. C., Kashani, K. B., & Mankad, S. v. 2016. Role of CVP to Guide Fluid Therapy in Chronic Heart Failure: Lessons From Cardiac Intensive Care. In *JACC: Cardiovascular Interventions* (Vol. 9, Issue 6, pp. 624–625). Elsevier Inc. <https://doi.org/10.1016/j.jcin.2015.12.278>
- Wali, U., Hussain, M. M., Wali, N., Nadeem, A., Majeed, F. 2019. Comparison of serum levels of Cystatin-C and traditional renal biomarkers for the early detection of pre-hypertensive nephropathy. *JPM. The Journal of the Pakistan Medical Association*, 69(3), 313–319. <http://www.ncbi.nlm.nih.gov/pubmed/30890820>
- Wang, M., Zhang, L., Yue, R., You, G., Zeng, R. 2016. Significance of cystatin C for early diagnosis of contrast-induced nephropathy in patients undergoing coronary angiography. *Medical Science Monitor*, 22, 2956–2961. <https://doi.org/10.12659/MSM.897241>
- Wang, Z. Y., Wang, Y. L., Wei, J., Jin, L., Wang, Z. C. 2020. Role of serum cystatin C in the prediction of contrast-induced nephropathy after intra-Arterial interventions. *Chinese Medical Journal*, 133(4), 408–414. <https://doi.org/10.1097/CM9.0000000000000641>
- Warwas, M., Piwowar A. 2011. Moczowa cystatyna C jako biomarker uszkodzenia kanalików nerkowych Urinary cystatin C as a biomarker of renal tubular injury. In *Postepy Hig Med Dosw (online)* (Vol. 65). <http://www.phmd.pl/fulltxt.php?ICID=957690>
- Wichmann, J. L., Katzberg, R. W., Litwin, S. E., Zwerner, P. L., de Cecco, C. N., Vogl, T. J., *et al.* 2015. Contrast-induced nephropathy. *Circulation*, 132(20), 1931–1936. <https://doi.org/10.1161/CIRCULATIONAHA.115.014672>
- Windecker, S., Kolh., P., Alfonso, F., Collet, J.P., Cremer, J., Falk, V., *et al.* 2014. 2014 ESC/EACTS guidelines on myocardial revascularization. *Kardiol Pol.* 72:1253-379.
- Zdziechowska, M., Gluba-Brzózka, A., Poliwczak, A. R., Franczyk, B., Kidawa, M., Zielinska, M., Rysz, J. 2020. Serum NGAL, KIM-1, IL-18, L-FABP: new biomarkers in the diagnostics of acute kidney injury (AKI) following invasive cardiology procedures. *International Urology and Nephrology*, 52(11), 2135–2143. <https://doi.org/10.1007/s11255-020-02530-x>
- Zhang, W. F., Zhang, T., Ding, D., Sun, S. Q., Wang, X. L., Chu, S. C., *et al.* 2017. Use of both serum cystatin C and creatinine as diagnostic criteria for contrast-induced acute kidney injury and its clinical implications. *Journal of the American Heart Association*, 6(1). <https://doi.org/10.1161/JAHA.116.004747>